While studies targeting K17 for anticancer drug development remain limited [21], a growing body of literature suggests that the expression of K17 correlates with clinical outcomes across various cancer types, establishing its role as a prognostic biomarker [22,23,24,25,26,27,28,29,30,31]. The gene discussed is KRT17; the disease is cancer.